EGFR Expression in Gallbladder Carcinoma in North Indian Population.

OBJECTIVE Gallbladder carcinoma is the most frequent biliary tract carcinoma with over all very poor prognosis. Epidermal growth factor receptor (EGFR) is known to be involved in carcinogenesis and overexpressed in various malignancies including head and neck, breast, lung and colon carcinomas. This study was done to explore the expression of EGFR in gallbladder carcinoma cases in the north Indian population so that it may be used as a therapeutic target in these patients. MATERIALS AND METHODS 59 cases of gallbladder carcinoma diagnosed by histopathological examination were included in study. Expression of EGFR was seen by immunohistochemistry method on histopathology slides. RESULTS Out of 59 gallbladder carcinoma cases 46 (78%) were female and 13 (22%) were male with female to male ratio of 3.54:1. Mean age was 51.71±11.32 years. On histopathological examination 51 (86.4%) cases were conventional adenocarcinoma, 2 (3.4%) adenosquamous carcinoma, 2 (3.4%) mucinous adenocarcinoma, 2 (3.4%) papillary adenocarcinoma, 1 (1.7%) signet ring cell carcinoma and 1 (1.7%) squamous cell carcinoma histological subtypes. EGFR expression was present in 31 (52.5%) of gallbladder carcinoma cases and strong EGFR expression was significantly associated with poor differentiation of tumour. CONCLUSION In our study EGFR was positive in the majority of gallbladder carcinoma cases. There was inverse correlation between differentiation of tumor and EGFR expression. Strong EGFR expression was significantly higher in poorly differentiated tumors compared to well differentiated tumors suggesting its role in prognosis. This also suggest that EGFR might have a role in tumor progression and aggressiveness. Therefore, EGFR have potential to be used as therapeutic target in significant number of patients. More larger sample studies are required to confirm our findings. EGFR may be further studied as therapeutic target in clinical trials in the Indian population to improve morbidity and mortality of gallbladder carcinoma patients. KEY WORDS EGFR Expression, Gallbladder Carcinoma, Immunohistochemistry, Targeted Therapy.

[1]  P. Tiwari,et al.  Clinical epidemiology of gallbladder cancer in North-Central India and association of immunological markers, NLR, MLR and PLR in the diagnostic/prognostic prediction of GBC. , 2021, Cancer treatment and research communications.

[2]  A. Saha,et al.  Role of EGFR and HER-2/NEU Expression in Gall Bladder Carcinoma (GBC) , 2021, Journal of Laboratory Physicians.

[3]  Ying-bin Liu,et al.  Overview of current targeted therapy in gallbladder cancer , 2020, Signal Transduction and Targeted Therapy.

[4]  V. Kapoor,et al.  Epidemiology of gallbladder cancer in India. , 2019, Chinese clinical oncology.

[5]  G. Abou-Alfa,et al.  Systemic therapy for gallbladder cancer. , 2019, Chinese clinical oncology.

[6]  Hui Shen,et al.  PLEK2 promotes gallbladder cancer invasion and metastasis through EGFR/CCL2 pathway , 2019, Journal of Experimental & Clinical Cancer Research.

[7]  Yu Fan,et al.  EGFR Target Therapy Combined with Gemox for Advanced Biliary Tract Cancers: a Meta-analysis based on RCTs , 2018, Journal of Cancer.

[8]  Sameer Gupta,et al.  Investigation of targetable predictive and prognostic markers in gallbladder carcinoma. , 2018, Journal of gastrointestinal oncology.

[9]  K. Rudresh,et al.  Epidermal growth factor receptor: Role in human cancer , 2017, Indian journal of dental research : official publication of Indian Society for Dental Research.

[10]  Zheng Wang,et al.  The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR , 2016, Journal of experimental & clinical cancer research : CR.

[11]  M. Khan,et al.  Epidermal growth factor receptor expression in carcinoma gallbladder: A prospective study in Indian scenario. , 2016, Journal of cancer research and therapeutics.

[12]  T. Goetze Gallbladder carcinoma: Prognostic factors and therapeutic options. , 2015, World journal of gastroenterology.

[13]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[14]  R. Artigiani-Neto,et al.  EVALUATION OF P53, E-CADHERIN, COX-2, AND EGFR PROTEIN IMUNNOEXPRESSION ON PROGNOSTIC OF RESECTED GALLBLADDER CARCINOMA , 2014, Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery.

[15]  H. Lenz,et al.  S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma , 2014, British Journal of Cancer.

[16]  C. Tzeng,et al.  EGFR Nuclear Import in Gallbladder Carcinoma: Nuclear Phosphorylated EGFR Upregulates iNOS Expression and Confers Independent Prognostic Impact , 2012, Annals of Surgical Oncology.

[17]  K. Mody,et al.  Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report , 2010, BMC Cancer.

[18]  S. Kakar,et al.  Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder. , 2010, Human pathology.

[19]  A. Zhu,et al.  Current management of gallbladder carcinoma. , 2010, The oncologist.

[20]  B. Mehrotra,et al.  EGFR Expression in Gallbladder Carcinoma in North America , 2008, International journal of medical sciences.

[21]  P. Philip,et al.  Phase II study of erlotinib in patients with advanced biliary cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  C. la Vecchia,et al.  Gallbladder cancer worldwide: Geographical distribution and risk factors , 2006, International journal of cancer.

[23]  Ying Feng,et al.  [Significance of expression of epidermal growth factor (EGF) and its receptor (EGFR) in chronic cholecystitis and gallbladder carcinoma]. , 2003, Ai zheng = Aizheng = Chinese journal of cancer.

[24]  C. S. Lee,et al.  Epidermal growth factor receptor immunoreactivity in gallbladder and extrahepatic biliary tract tumours. , 1995, Pathology, research and practice.

[25]  N. Husain,et al.  EGFR and HER-2/neu Expression in Gallbladder Carcinoma: An Institutional Experience. , 2016, The Gulf journal of oncology.